Loading...
•
Dec 31, 2021
Aadi Bioscience Q4 2021 Earnings Report
Aadi Bioscience reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.
Key Takeaways
Aadi Bioscience reported a net loss attributable to common stockholders of $16.0 million for the fourth quarter of 2021, compared to a net income of $7.8 million in the prior year quarter. As of December 31, 2021, cash and cash equivalents totaled $149.0 million. FYARRO was approved by the FDA on November 22, 2021, and launched in February 2022.
FYARRO was approved on November 22, 2021 and launched on February 23, 2022.
FYARRO added to NCCN® Guidelines as the only preferred therapy to treat malignant PEComa.
PRECISION 1 tumor agnostic study for TSC1 or TSC2 alterations open for enrollment.
Ended fourth quarter 2021 with $149.0 million in cash and cash equivalents.
Aadi Bioscience
Aadi Bioscience
Forward Guidance
Based on current plans, Aadi Bioscience expects cash and cash equivalents to fund operations into 2024.